Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.00.

Several analysts have recently issued reports on PYXS shares. Jefferies Financial Group reissued a “buy” rating and set a $10.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, May 16th. Finally, Stifel Nicolaus initiated coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $3.36 on Friday. The company has a market cap of $197.86 million, a PE ratio of -2.47 and a beta of 1.29. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85. The company has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $4.23.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The business had revenue of $16.15 million during the quarter, compared to analysts’ expectations of $4.25 million. On average, analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current year.

Institutional Trading of Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Fullcircle Wealth LLC acquired a new position in shares of Pyxis Oncology during the second quarter valued at $40,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology during the 1st quarter valued at about $59,000. Cetera Advisors LLC bought a new position in Pyxis Oncology in the 1st quarter worth about $100,000. Schulhoff & Co. Inc. increased its stake in shares of Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after purchasing an additional 20,000 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Pyxis Oncology by 56.0% during the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after buying an additional 20,901 shares during the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.